SK5452003A3 - Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders - Google Patents

Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders Download PDF

Info

Publication number: SK5452003A3
Authority: SK; Slovakia
Prior art keywords: cancer; pentamidine; chlorpromazine; drug; group
Prior art date: 2000-11-06

Application number

SK545-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Alexis Borisy

Curtis Keith

Michael A Foley

Brent R Stockwell

Original Assignee

Combinatorx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-06

Filing date

2001-10-30

Publication date

2004-07-07

2001-10-30 Application filed by Combinatorx Inc filed Critical Combinatorx Inc

2004-07-07 Publication of SK5452003A3 publication Critical patent/SK5452003A3/sk

Links

ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 title claims abstract description 59
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 title claims abstract description 57
229960004448 pentamidine Drugs 0.000 title claims abstract description 50
229960001076 chlorpromazine Drugs 0.000 title claims abstract description 49
239000003814 drug Substances 0.000 title claims description 48
229940079593 drug Drugs 0.000 title claims description 41
238000011282 treatment Methods 0.000 title description 14
230000001613 neoplastic effect Effects 0.000 title 1
206010028980 Neoplasm Diseases 0.000 claims abstract description 52
201000011510 cancer Diseases 0.000 claims abstract description 32
208000035269 cancer or benign tumor Diseases 0.000 claims abstract description 10
230000012010 growth Effects 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims description 13
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
238000007918 intramuscular administration Methods 0.000 claims description 8
201000005202 lung cancer Diseases 0.000 claims description 8
208000020816 lung neoplasm Diseases 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 5
208000026310 Breast neoplasm Diseases 0.000 claims description 4
208000003849 large cell carcinoma Diseases 0.000 claims description 4
206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
208000003174 Brain Neoplasms Diseases 0.000 claims description 3
206010008342 Cervix carcinoma Diseases 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
206010025323 Lymphomas Diseases 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
206010038389 Renal cancer Diseases 0.000 claims description 3
206010039491 Sarcoma Diseases 0.000 claims description 3
208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
206010057644 Testis cancer Diseases 0.000 claims description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
208000009956 adenocarcinoma Diseases 0.000 claims description 3
230000004663 cell proliferation Effects 0.000 claims description 3
201000010881 cervical cancer Diseases 0.000 claims description 3
208000029742 colonic neoplasm Diseases 0.000 claims description 3
206010017758 gastric cancer Diseases 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
201000010982 kidney cancer Diseases 0.000 claims description 3
208000032839 leukemia Diseases 0.000 claims description 3
201000007270 liver cancer Diseases 0.000 claims description 3
208000014018 liver neoplasm Diseases 0.000 claims description 3
201000005296 lung carcinoma Diseases 0.000 claims description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
201000002528 pancreatic cancer Diseases 0.000 claims description 3
208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
201000000849 skin cancer Diseases 0.000 claims description 3
201000011549 stomach cancer Diseases 0.000 claims description 3
201000003120 testicular cancer Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 2
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
208000000453 Skin Neoplasms Diseases 0.000 claims description 2
206010038038 rectal cancer Diseases 0.000 claims description 2
201000001275 rectum cancer Diseases 0.000 claims description 2
206010046766 uterine cancer Diseases 0.000 claims description 2
208000002495 Uterine Neoplasms Diseases 0.000 claims 1
239000002207 metabolite Substances 0.000 abstract description 12
238000000034 method Methods 0.000 abstract description 9
150000001875 compounds Chemical class 0.000 description 64
239000000203 mixture Substances 0.000 description 54
210000004027 cell Anatomy 0.000 description 40
238000009472 formulation Methods 0.000 description 30
-1 metotrimeprazine Chemical compound 0.000 description 29
230000001028 anti-proliverative effect Effects 0.000 description 24
238000013270 controlled release Methods 0.000 description 19
239000003826 tablet Substances 0.000 description 15
239000011159 matrix material Substances 0.000 description 13
239000000243 solution Substances 0.000 description 11
239000004480 active ingredient Substances 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
239000008186 active pharmaceutical agent Substances 0.000 description 8
239000011248 coating agent Substances 0.000 description 8
238000000576 coating method Methods 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
229940088679 drug related substance Drugs 0.000 description 8
230000000694 effects Effects 0.000 description 8
YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
239000003883 ointment base Substances 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
MMURVNDSFNJHAM-OWOJBTEDSA-N 4-[(e)-2-(4-carbamimidoylphenyl)ethenyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1\C=C\C1=CC=C(C(N)=N)C=C1 MMURVNDSFNJHAM-OWOJBTEDSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
235000014113 dietary fatty acids Nutrition 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000000194 fatty acid Substances 0.000 description 6
229930195729 fatty acid Natural products 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000004005 microsphere Substances 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
229920000728 polyester Polymers 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
208000000587 small cell lung carcinoma Diseases 0.000 description 6
239000000600 sorbitol Substances 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
201000009030 Carcinoma Diseases 0.000 description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
230000000561 anti-psychotic effect Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
208000019065 cervical carcinoma Diseases 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
239000002502 liposome Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
229920000609 methyl cellulose Polymers 0.000 description 5
235000010981 methylcellulose Nutrition 0.000 description 5
239000001923 methylcellulose Substances 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
235000010356 sorbitol Nutrition 0.000 description 5
229920002554 vinyl polymer Polymers 0.000 description 5
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
229930012538 Paclitaxel Natural products 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000002998 adhesive polymer Substances 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
239000000969 carrier Substances 0.000 description 4
TUESWZZJYCLFNL-DAFODLJHSA-N chembl1301 Chemical compound C1=CC(C(=N)N)=CC=C1\C=C\C1=CC=C(C(N)=N)C=C1O TUESWZZJYCLFNL-DAFODLJHSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
239000007943 implant Substances 0.000 description 4
239000003094 microcapsule Substances 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
229960001592 paclitaxel Drugs 0.000 description 4
150000002990 phenothiazines Chemical class 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
206010041067 Small cell lung cancer Diseases 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
230000003291 dopaminomimetic effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
229940014259 gelatin Drugs 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000000017 hydrogel Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
229950005911 hydroxystilbamidine Drugs 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
239000002105 nanoparticle Substances 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000002674 ointment Substances 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
DMABBVCVVXMJDH-UHFFFAOYSA-N phenamidine Chemical compound C1=CC(C(=N)N)=CC=C1OC1=CC=C(C(N)=N)C=C1 DMABBVCVVXMJDH-UHFFFAOYSA-N 0.000 description 3
229950000688 phenothiazine Drugs 0.000 description 3
229920000747 poly(lactic acid) Polymers 0.000 description 3
229920005597 polymer membrane Polymers 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
229920001592 potato starch Polymers 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
210000000664 rectum Anatomy 0.000 description 3
239000007921 spray Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
KRUVSRGJKCHYMY-UHFFFAOYSA-N 1,3-bis(3-carbamimidoylphenyl)urea Chemical compound NC(=N)C1=CC=CC(NC(=O)NC=2C=C(C=CC=2)C(N)=N)=C1 KRUVSRGJKCHYMY-UHFFFAOYSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
KXHZWUUTWSKONE-UHFFFAOYSA-N 4-[4-(4-carbamimidoylphenoxy)butoxy]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCOC1=CC=C(C(N)=N)C=C1 KXHZWUUTWSKONE-UHFFFAOYSA-N 0.000 description 2
IUJKKCRARYRWFG-UHFFFAOYSA-N 4-[7-(4-carbamimidoylphenoxy)heptoxy]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCCOC1=CC=C(C(N)=N)C=C1 IUJKKCRARYRWFG-UHFFFAOYSA-N 0.000 description 2
CFQYOTZLYKJVKS-UHFFFAOYSA-N 4-[9-(4-carbamimidoylphenoxy)nonoxy]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCCCCOC1=CC=C(C(N)=N)C=C1 CFQYOTZLYKJVKS-UHFFFAOYSA-N 0.000 description 2
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
208000000230 African Trypanosomiasis Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
231100000111 LD50 Toxicity 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
229930183665 actinomycin Natural products 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
229950007857 amicarbalide Drugs 0.000 description 2
230000003474 anti-emetic effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000003904 antiprotozoal agent Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
235000013871 bee wax Nutrition 0.000 description 2
239000012166 beeswax Substances 0.000 description 2
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229950004398 broxuridine Drugs 0.000 description 2
235000019437 butane-1,3-diol Nutrition 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000004203 carnauba wax Substances 0.000 description 2
235000013869 carnauba wax Nutrition 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
239000007859 condensation product Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
229960000493 dibrompropamidine Drugs 0.000 description 2
GMJFVGRUYJHMCO-UHFFFAOYSA-N dibrompropamidine Chemical compound BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br GMJFVGRUYJHMCO-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
230000029142 excretion Effects 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000003349 gelling agent Substances 0.000 description 2
229940075507 glyceryl monostearate Drugs 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
150000002475 indoles Chemical class 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
239000006187 pill Substances 0.000 description 2
229960001237 podophyllotoxin Drugs 0.000 description 2
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
WTFXJFJYEJZMFO-UHFFFAOYSA-N propamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1 WTFXJFJYEJZMFO-UHFFFAOYSA-N 0.000 description 2
229960003761 propamidine Drugs 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000552 rheumatic effect Effects 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
229960002066 vinorelbine Drugs 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
UVOIBTBFPOZKGP-CQSZACIVSA-N 1-[10-[(2r)-2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one Chemical compound C1=CC=C2N(C[C@@H](C)N(C)C)C3=CC(C(=O)CC)=CC=C3SC2=C1 UVOIBTBFPOZKGP-CQSZACIVSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
CQVKMVQRSNNAGO-UHFFFAOYSA-N 2-[4-formyl-3-methyl-n-(2-methylsulfonyloxyethyl)anilino]ethyl methanesulfonate Chemical class CC1=CC(N(CCOS(C)(=O)=O)CCOS(C)(=O)=O)=CC=C1C=O CQVKMVQRSNNAGO-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
UUWRRYQMUCNKRK-UHFFFAOYSA-N 3-methoxy-4-propoxybenzenecarboximidamide Chemical compound CCCOC1=CC=C(C(N)=N)C=C1OC UUWRRYQMUCNKRK-UHFFFAOYSA-N 0.000 description 1
UDKVBVICMUEIKS-UHFFFAOYSA-N 4-[(6-chloro-2-methoxyacridin-9-yl)azaniumyl]pentyl-diethylazanium;dichloride Chemical compound Cl.Cl.C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 UDKVBVICMUEIKS-UHFFFAOYSA-N 0.000 description 1
BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000499489 Castor canadensis Species 0.000 description 1
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229940127333 Dopamine D2 Antagonists Drugs 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
241000222727 Leishmania donovani Species 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100494360 Mus musculus C1galt1c1 gene Proteins 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
108010042309 Netropsin Proteins 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010033372 Pain and discomfort Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
241000223105 Trypanosoma brucei Species 0.000 description 1
241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
150000001409 amidines Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000001775 anti-pathogenic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
206010006007 bone sarcoma Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
210000000424 bronchial epithelial cell Anatomy 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
230000005773 cancer-related death Effects 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
201000006662 cervical adenocarcinoma Diseases 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
108091008690 chemoreceptors Proteins 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001791 clebopride Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical class COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
229950007095 diminazene Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930182480 glucuronide Natural products 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000774 hypoallergenic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000001985 kidney epithelial cell Anatomy 0.000 description 1
239000002650 laminated plastic Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
235000014666 liquid concentrate Nutrition 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
NXMXPVQZFYYPGD-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate Chemical compound COC(=O)C=C.COC(=O)C(C)=C NXMXPVQZFYYPGD-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000002746 orthostatic effect Effects 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007833 oxidative deamination reaction Methods 0.000 description 1
238000006274 oxidative n-demethylation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229950007538 pecazine Drugs 0.000 description 1
CBHCDHNUZWWAPP-UHFFFAOYSA-N pecazine Chemical compound C1N(C)CCCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 CBHCDHNUZWWAPP-UHFFFAOYSA-N 0.000 description 1
229960002195 perazine Drugs 0.000 description 1
WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
239000002304 perfume Substances 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
229960003634 pimozide Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
229930010796 primary metabolite Natural products 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
239000000047 product Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
239000001294 propane Substances 0.000 description 1
229960005036 propiomazine Drugs 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
210000000064 prostate epithelial cell Anatomy 0.000 description 1
239000011814 protection agent Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
230000007480 spreading Effects 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
108010042747 stallimycin Proteins 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
125000001302 tertiary amino group Chemical group 0.000 description 1
230000002381 testicular Effects 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
229960004728 thiopropazate Drugs 0.000 description 1
AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
208000012991 uterine carcinoma Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

SK545-2003A 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders SK5452003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/706,929 US6569853B1 (en)	2000-11-06	2000-11-06	Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
PCT/US2001/047959 WO2002058684A2 (en)	2000-11-06	2001-10-30	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Publications (1)

Publication Number	Publication Date
SK5452003A3 true SK5452003A3 (en)	2004-07-07

Family

ID=24839666

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK545-2003A SK5452003A3 (en)	2000-11-06	2001-10-30	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Country Status (29)

Country	Link
US (4)	US6569853B1 (is)
EP (1)	EP1339399B1 (is)
JP (1)	JP2004517915A (is)
KR (1)	KR100720205B1 (is)
CN (1)	CN1484525A (is)
AR (1)	AR035500A1 (is)
AT (1)	ATE318590T1 (is)
AU (1)	AU2002246636B8 (is)
BG (1)	BG107831A (is)
BR (1)	BR0115166A (is)
CA (1)	CA2436799C (is)
CY (1)	CY1105501T1 (is)
DE (1)	DE60117615T2 (is)
DK (1)	DK1339399T3 (is)
EE (1)	EE200300212A (is)
ES (1)	ES2258566T3 (is)
HR (1)	HRP20030460A2 (is)
HU (1)	HUP0400529A3 (is)
IL (1)	IL155795A0 (is)
IS (1)	IS2457B (is)
MX (1)	MXPA03003960A (is)
NO (1)	NO20032036L (is)
NZ (1)	NZ525773A (is)
PL (1)	PL362690A1 (is)
PT (1)	PT1339399E (is)
RU (1)	RU2286769C2 (is)
SK (1)	SK5452003A3 (is)
TW (1)	TWI259077B (is)
WO (1)	WO2002058684A2 (is)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60042245D1 (de) *	1999-11-16	2009-07-02	Oncozyme Pharma Inc	Pentamidine zur behandlung von krebs
DE10015818A1 (de) *	2000-03-30	2001-10-18	Infineon Technologies Ag	Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6569853B1 (en) *	2000-11-06	2003-05-27	Combinatorx, Incorporated	Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) *	2000-12-18	2003-03-13	Wockhardt Limited	Novel in-situ forming controlled release microcarrier delivery system
WO2002057244A1 (en) *	2001-01-19	2002-07-25	Cytokinetics, Inc.	Phenothiazine kinesin inhibitors
US6693125B2 (en) *	2001-01-24	2004-02-17	Combinatorx Incorporated	Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) *	2001-03-06	2002-09-12	Prendergast Patrick T	Combination therapy for reduction of toxycity of chemotherapeutic agents
ATE401880T1 (de) *	2001-05-31	2008-08-15	Cleveland Clinic Foundation	Ptpase-inhibitoren und verfahren zu ihrer verwendung
FR2825279B1 (fr) *	2001-06-01	2005-04-08	Molecular Engines Lab	Medicament utile dans le traitement du cancer
US20050215629A1 (en) *	2001-09-07	2005-09-29	Taolin Yi	PTPase inhibitors and methods of using the same
US20040010045A1 (en) *	2001-09-07	2004-01-15	Taolin Yi	Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
CA2459793A1 (en)	2001-09-07	2003-08-28	The Cleveland Clinic Foundation	Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
AU2004201240B2 (en) *	2001-09-27	2008-08-07	Bar Ilan University	Conjugated Psychotropic Drugs and Uses Thereof
US7544681B2 (en) *	2001-09-27	2009-06-09	Ramot At Tel Aviv University Ltd.	Conjugated psychotropic drugs and uses thereof
US8053477B2 (en) *	2002-03-29	2011-11-08	University Of Maryland, Baltimore	Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
AU2003241346A1 (en) *	2002-05-01	2003-11-17	The Cleveland Clinic Foundation	Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003256511A1 (en) *	2002-07-11	2004-02-02	Combinatorx, Incorporated	Combinations of drugs for the treatment of neoplasms
ES2343411T3 (es) *	2003-03-26	2010-07-30	Synergy Biosystems Ltd.	Procedimientos para identificar agentes biologicamente activos y combinaciones sinergicas.
CA2534816A1 (en) *	2003-06-12	2004-12-23	Evan Newell	Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050054708A1 (en) *	2003-07-28	2005-03-10	Nichols Matthew James	Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) *	2003-08-25	2005-04-14	Nichols M. James	Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
EP1670477A2 (en) *	2003-09-18	2006-06-21	CombinatoRx, Incorporated	Combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) *	2003-11-12	2005-07-21	Nichols M. J.	Combinations for the treatment of proliferative diseases
US20050100508A1 (en) *	2003-11-12	2005-05-12	Nichols M. J.	Methods for identifying drug combinations for the treatment of proliferative diseases
TW200526777A (en) *	2003-11-12	2005-08-16	Combinatorx Inc	Combinations for the treatment of proliferative diseases
US8623864B2 (en)	2003-11-13	2014-01-07	Noa Sic Aps	Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
US7510710B2 (en)	2004-01-08	2009-03-31	The Regents Of The University Of Colorado	Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US7262223B2 (en)	2004-01-23	2007-08-28	Neurochem (International) Limited	Amidine derivatives for treating amyloidosis
US20100173864A1 (en)	2004-03-29	2010-07-08	Cheng Jin Q	Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en)	2004-03-29	2011-01-13	Cheng Jin Q	Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
EP2574341B1 (en)	2004-03-29	2017-03-29	University Of South Florida	Effective treatment of tumors and cancer with triciribine phosphate
US20100009928A1 (en)	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en)	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en)	2004-03-29	2010-02-04	Cheng Jin Q	Compositions including triciribine and trastuzumab and methods of use thereof
MXPA06012566A (es)	2004-04-30	2007-05-09	Bkg Pharma Aps	Tratamiento de enfermedades infecciosas.
WO2005117847A2 (en) *	2004-06-02	2005-12-15	Combinatorx, Incorporated	Methods and compounds for the treatment of neoplasms
US20080269259A1 (en) *	2005-01-19	2008-10-30	The Trustees Of The University Of Pennsylvania	Regulation of Autophagy and Cell Survival
TW200719903A (en) *	2005-04-19	2007-06-01	Combinatorx Inc	Compositions for the treatment of neoplasms
JP2008539238A (ja) *	2005-04-28	2008-11-13	ザリージェンツオブザユニバーシティオブコロラド	治療用二機能性化合物
US8329753B2 (en) *	2005-05-02	2012-12-11	The Regents Of The University Of Colorado	Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition
JP5700909B2 (ja) *	2005-05-04	2015-04-15	メディゲーネアクチエンゲゼルシャフトＭｅｄｉＧｅｎｅＡＧ	パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
DE102005024017A1 (de) *	2005-05-25	2006-11-30	Merck Patent Gmbh	Chinazolinone
JP5284779B2 (ja) *	2005-06-07	2013-09-11	ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド	コンジュゲート化された向精神薬の新規な塩およびその調製方法
CN1870631B (zh) *	2005-11-11	2010-04-14	华为技术有限公司	媒体网关的门控方法
WO2007082052A2 (en) *	2006-01-11	2007-07-19	The Cleveland Clinic Foundation	Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
RU2448697C2 (ru)	2006-03-22	2012-04-27	Медигене Аг	Лечение рака молочной железы, негативного по трем рецепторам
WO2007149381A2 (en) *	2006-06-19	2007-12-27	The Cleveland Clinic Foundation	Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080226596A1 (en) *	2006-06-19	2008-09-18	Taolin Yi	Therapeutic compositions and methods useful in treating hepatitis
CN101511388B (zh) *	2006-07-17	2012-10-24	特拉维夫大学拉莫特有限公司	含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
WO2008080398A1 (en) *	2007-01-05	2008-07-10	Bkg Pharma Aps	Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
JP5201744B2 (ja) *	2007-01-09	2013-06-05	フォヴェアファルマシューティカル	眼内注射装置
DE102007013854A1 (de)	2007-03-20	2008-09-25	Merck Patent Gmbh	Tetrahydrochinoline
DE102007013855A1 (de)	2007-03-20	2008-09-25	Merck Patent Gmbh	Substituierte Tetrahydrochinoline
DE102007013856A1 (de)	2007-03-20	2008-09-25	Merck Patent Gmbh	Substituierte Tetrahydropyrrolochinoline
CA2687715A1 (en) *	2007-05-09	2008-11-20	Traffick Therapeutics Inc.	Screening assay to identify correctors of protein trafficking defects
CN101138558B (zh) *	2007-09-13	2010-08-25	汕头大学医学院	喷他脒及死亡结构域受体配体联合应用
WO2009043902A1 (en) *	2007-10-05	2009-04-09	Universite De Mons Hainaut	Bisbenzimidazoles as antimalarial agents
WO2009101616A1 (en)	2008-02-11	2009-08-20	Ramot At Tel Aviv University Ltd.	Novel conjugates for treating neurodegenerative diseases and disorders
US8835506B2 (en)	2008-06-05	2014-09-16	Stc.Unm	Methods and related compositions for the treatment of cancer
US20100035858A1 (en) *	2008-07-18	2010-02-11	Immune Control, Inc.	Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor
US8993625B2 (en)	2009-03-11	2015-03-31	Stable Solutions Llc	Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en)	2009-03-11	2015-05-19	Stable Solutions Llc	Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
JP2012525371A (ja) *	2009-05-01	2012-10-22	オンコザイム・ファーマ・インコーポレイテッド	癌を治療するためのペンタミジンの組み合わせ
KR20120100706A (ko)	2009-05-20	2012-09-12	유니베르시떼 드 제네브	암 개시세포의 미토콘드리아 활성 저해제 및 이의 용도
WO2011035225A1 (en) *	2009-09-21	2011-03-24	President And Fellows Of Harvard College	Synergistic combination therapy
CA2782514A1 (en) *	2009-12-09	2011-06-16	Biolinerx Ltd.	Methods of improving cognitive functions
WO2011133966A2 (en) *	2010-04-23	2011-10-27	University Of Florida Research Foundation,Inc.	Method and compositions for treating ace2-related disorders
US8916610B2 (en)	2010-09-22	2014-12-23	Ramot At Tel-Aviv University Ltd.	Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
DK2550963T3 (en) *	2011-07-25	2017-01-30	Dritte Patentportfolio Beteili	Pentamidine amidoxime acid esters as prodrugs and their use as a drug.
EP3473254B1 (en) *	2011-08-02	2024-01-24	Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH	Phenothiazine derivatives for the treatment of autoimmune diseases
WO2014086478A1 (en) *	2012-12-03	2014-06-12	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Inhibitors of malt1 protease
US9375411B2 (en) *	2012-12-21	2016-06-28	Verlyx Pharma Inc.	Uses and methods for the treatment of liver diseases or conditions
RU2530651C1 (ru) *	2013-11-06	2014-10-10	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук	Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии
KR101538264B1 (ko) *	2014-01-24	2015-07-20	계명대학교 산학협력단	티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
TWI735413B (zh) *	2014-06-02	2021-08-11	國立陽明交通大學	抗藥性癌症之治療方法
CN105153042B (zh) *	2015-07-17	2017-11-24	四川大学	一种化合物及其在制备治疗可卡因成瘾的药物中的用途
US20210378992A1 (en) *	2018-10-19	2021-12-09	Auransa Inc.	Methods for treating a subtype of small cell lung cancer
WO2020132636A1 (en)	2018-12-20	2020-06-25	Auransa Inc.	Analogues of pentamidine and uses therefor
CN109793727A (zh) *	2019-03-13	2019-05-24	湖北科技学院	一种有效抗恶性肿瘤的药物组合物及其应用
KR102562739B1 (ko) *	2020-09-11	2023-08-03	연세대학교 산학협력단	암의 기원 세포의 사멸용 약학적 조성물
CN114588163A (zh) *	2020-12-04	2022-06-07	中国福利会国际和平妇幼保健院	盐酸氯丙嗪在治疗子宫内膜癌中的应用
KR102315103B1 (ko) *	2021-01-21	2021-10-20	주식회사 뉴캔서큐어바이오	티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2645640A (en) *		1953-07-14		Phenthiazine derivatives
US5A (en) *		1836-08-10	Thomas Blanchard	Machine for mortising solid wooden shells of ships' tackle-blocks
GB1288376A (is)	1968-10-29	1972-09-06
DE3827974A1 (de) *	1988-08-18	1990-02-22	Boehringer Mannheim Gmbh	Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5104858A (en)	1988-09-29	1992-04-14	Yale University	Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) *	1991-02-25	1993-05-28	Patrinove	Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) *	1992-10-13	1995-06-27	University Of North Carolina	Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) *	1993-06-04	1995-08-22	Mitotix, Inc.	Methods of identifying inhibitors of cdc25 phosphatase
US5521189A (en) *	1994-05-06	1996-05-28	The University Of Nc At Ch	Methods of treating pneumocystis carinii pneumonia
US5602172A (en) *	1994-05-06	1997-02-11	The University Of North Carolina At Chapel Hill	Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5770585A (en)	1995-05-08	1998-06-23	Kaufman; Robert J.	Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) *	1995-06-07	1997-07-01	The University Of North Carolina At Chapel Hill	Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) *	1995-11-16	1998-03-03	The University Of North Carolina At Chapel Hill	Benzamidoxime prodrugs as antipneumocystic agents
WO1998000018A1 (en) *	1996-07-03	1998-01-08	Prm Pharmaceuticals, Inc.	Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea
US6008247A (en) *	1998-02-27	1999-12-28	The University Of North Carolina At Chapel Hill	2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
WO1999046237A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases
CA2340912C (en) *	1998-08-20	2008-11-18	University Of North Carolina At Chapel Hill	Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
ES2275362T3 (es) *	1998-09-17	2007-06-01	The University Of North Carolina At Chapel Hill	Actividad antifungica de moleculas dicationicas.
JP3679943B2 (ja) *	1999-03-02	2005-08-03	大日本印刷株式会社	パターン形成体の製造方法
DE60042245D1 (de)	1999-11-16	2009-07-02	Oncozyme Pharma Inc	Pentamidine zur behandlung von krebs
US6777433B2 (en) *	1999-12-22	2004-08-17	Merck Frosst Canada & Co.	Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
AU2001258784A1 (en) *	2000-05-22	2001-12-03	Takeda Chemical Industries Ltd.	Tyrosine phosphatase inhibitors
US6569853B1 (en) *	2000-11-06	2003-05-27	Combinatorx, Incorporated	Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) *	2000-11-15	2003-11-04	Parker Hughes Institute	Vanadium compounds as anti-proliferative agents
US6693125B2 (en) *	2001-01-24	2004-02-17	Combinatorx Incorporated	Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) *	2001-09-07	2003-08-28	Taolin Yi	PTPase inhibitors and methods of using the same
AU2003256511A1 (en) *	2002-07-11	2004-02-02	Combinatorx, Incorporated	Combinations of drugs for the treatment of neoplasms
US20050054708A1 (en) *	2003-07-28	2005-03-10	Nichols Matthew James	Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) *	2003-08-25	2005-04-14	Nichols M. James	Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
EP1670477A2 (en) *	2003-09-18	2006-06-21	CombinatoRx, Incorporated	Combinations of drugs for the treatment of neoplasms
US20050100508A1 (en) *	2003-11-12	2005-05-12	Nichols M. J.	Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) *	2003-11-12	2005-07-21	Nichols M. J.	Combinations for the treatment of proliferative diseases

2000
- 2000-11-06 US US09/706,929 patent/US6569853B1/en not_active Expired - Fee Related
2001
- 2001-10-30 AT AT01994213T patent/ATE318590T1/de not_active IP Right Cessation
- 2001-10-30 BR BR0115166-5A patent/BR0115166A/pt not_active Application Discontinuation
- 2001-10-30 WO PCT/US2001/047959 patent/WO2002058684A2/en not_active Ceased
- 2001-10-30 KR KR1020037006212A patent/KR100720205B1/ko not_active Expired - Fee Related
- 2001-10-30 SK SK545-2003A patent/SK5452003A3/sk not_active Application Discontinuation
- 2001-10-30 PT PT01994213T patent/PT1339399E/pt unknown
- 2001-10-30 HU HU0400529A patent/HUP0400529A3/hu unknown
- 2001-10-30 NZ NZ525773A patent/NZ525773A/en unknown
- 2001-10-30 CN CNA018217230A patent/CN1484525A/zh active Pending
- 2001-10-30 PL PL01362690A patent/PL362690A1/xx not_active Application Discontinuation
- 2001-10-30 HR HR20030460A patent/HRP20030460A2/hr not_active Application Discontinuation
- 2001-10-30 RU RU2003116898/14A patent/RU2286769C2/ru not_active IP Right Cessation
- 2001-10-30 CA CA002436799A patent/CA2436799C/en not_active Expired - Fee Related
- 2001-10-30 DK DK01994213T patent/DK1339399T3/da active
- 2001-10-30 ES ES01994213T patent/ES2258566T3/es not_active Expired - Lifetime
- 2001-10-30 DE DE60117615T patent/DE60117615T2/de not_active Expired - Fee Related
- 2001-10-30 EE EEP200300212A patent/EE200300212A/xx unknown
- 2001-10-30 IL IL15579501A patent/IL155795A0/xx unknown
- 2001-10-30 JP JP2002559018A patent/JP2004517915A/ja active Pending
- 2001-10-30 AU AU2002246636A patent/AU2002246636B8/en not_active Ceased
- 2001-10-30 EP EP01994213A patent/EP1339399B1/en not_active Expired - Lifetime
- 2001-10-30 MX MXPA03003960A patent/MXPA03003960A/es active IP Right Grant
- 2001-11-06 TW TW090127505A patent/TWI259077B/zh not_active IP Right Cessation
- 2001-11-06 AR ARP010105193A patent/AR035500A1/es not_active Application Discontinuation
2003
- 2003-01-21 US US10/347,714 patent/US6846816B2/en not_active Expired - Fee Related
- 2003-05-05 IS IS6806A patent/IS2457B/is unknown
- 2003-05-06 NO NO20032036A patent/NO20032036L/no not_active Application Discontinuation
- 2003-05-20 BG BG107831A patent/BG107831A/bg unknown
2004
- 2004-12-28 US US11/024,303 patent/US7148216B2/en not_active Expired - Fee Related
2006
- 2006-05-19 CY CY20061100653T patent/CY1105501T1/el unknown
- 2006-12-07 US US11/635,704 patent/US20070099906A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0400529A3 (en)	2006-02-28
CY1105501T1 (el)	2010-04-28
JP2004517915A (ja)	2004-06-17
IS2457B (is)	2008-11-15
AR035500A1 (es)	2004-06-02
EP1339399A2 (en)	2003-09-03
DE60117615D1 (de)	2006-04-27
KR100720205B1 (ko)	2007-05-21
AU2002246636B2 (en)	2005-12-01
CA2436799C (en)	2007-12-18
NZ525773A (en)	2005-04-29
AU2002246636B8 (en)	2006-01-19
NO20032036L (no)	2003-07-04
TWI259077B (en)	2006-08-01
WO2002058684A3 (en)	2003-04-17
HRP20030460A2 (en)	2005-04-30
US20050192274A1 (en)	2005-09-01
EE200300212A (et)	2003-08-15
IS6806A (is)	2003-05-05
RU2286769C2 (ru)	2006-11-10
US20070099906A1 (en)	2007-05-03
EP1339399B1 (en)	2006-03-01
WO2002058684A2 (en)	2002-08-01
CN1484525A (zh)	2004-03-24
ES2258566T3 (es)	2006-09-01
BG107831A (bg)	2004-02-27
KR20030048460A (ko)	2003-06-19
DE60117615T2 (de)	2006-11-09
HUP0400529A2 (hu)	2004-06-28
IL155795A0 (en)	2003-12-23
US20030166642A1 (en)	2003-09-04
US6569853B1 (en)	2003-05-27
US7148216B2 (en)	2006-12-12
PT1339399E (pt)	2006-07-31
DK1339399T3 (da)	2006-06-19
BR0115166A (pt)	2003-12-30
CA2436799A1 (en)	2002-08-01
MXPA03003960A (es)	2004-09-10
PL362690A1 (en)	2004-11-02
US6846816B2 (en)	2005-01-25
ATE318590T1 (de)	2006-03-15
NO20032036D0 (no)	2003-05-06

Legal Events

Date	Code	Title	Description
2011-05-06	FC9A	Refused patent application

Publication	Publication Date	Title
SK5452003A3 (en)	2004-07-07	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
US6693125B2 (en)	2004-02-17	Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
AU2002246636A1 (en)	2003-02-06	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
ES2438535T3 (es)	2014-01-17	Taurolidina o taurultamo para uso en el tratamiento de tumores de próstata, de colon, de pulmón y para el tratamiento del glioblastoma multiforme recurrente
US20050013853A1 (en)	2005-01-20	Anti-proliferative drugs
US20150283136A1 (en)	2015-10-08	Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
HRP20050115A2 (en)	2005-10-31	Combinations of drugs for the treatment of neoplasms
US10736902B2 (en)	2020-08-11	Method of treating triple negative breast cancer
Bottorff et al.	1999	Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations
EP2207548B1 (en)	2013-05-22	Breast cancer therapy
PT99091B (pt)	1999-02-26	Processo para a preparacao de composicoes farmaceuticas contendo derivados da triazina e da pirimidina, como ingredientes activos, destinadas a reverter a resistencia aos agentes anticancerosos e antimalaricos
EP3782620B1 (en)	2023-12-20	Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia
AU2006200697A1 (en)	2006-03-09	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
US20220409582A1 (en)	2022-12-29	Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
CA2599884A1 (en)	2002-08-01	Combinations of drugs for the treatment of neoplastic disorders
WO2021048419A1 (en)	2021-03-18	Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
CZ20031240A3 (cs)	2003-12-17	Kombinace léků (např. chlorpromazinu a pentamidinu) pro léčbu nádorových onemocnění, způsob jejich léčby, farmaceutické prostředky jejich léčby a farmaceutické balení
HK1063744A (en)	2005-01-14	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
WO2021048418A1 (en)	2021-03-18	Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma